Natco Pharma Q1 Profit Falls 57% Amid Lower Lenalidomide Sales; Interim Dividend Declared
Natco Pharma reported a 57% decline in consolidated net profit to Rs 206.5 crore for the first quarter ended June 2026, primarily due to lower sales of its generic cancer drug lenalidomide. Consolidated revenue fell about 45% year-on-year to Rs 735.2 crore, with international formulations revenue dropping significantly while domestic formulations and API segments showed growth. Total expenses decreased compared to the previous year. The company declared an interim dividend of Rs 1.50 per share and plans to raise Rs 2,000 crore through securities issuance, subject to approvals.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (44/100). Lens Score 35/100.
Outlets measured: businessstandard, economictimes, news18, thefinancialexpress. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (42–48/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thefinancialexpress broke this story on 14 Aug, 09:41 am. Other outlets followed.